uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Comparative evaluation of In-111-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Preclinical PET Platform.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Preclinical PET Platform.
Show others and affiliations
2015 (English)In: Oncology Reports, ISSN 1021-335X, Vol. 34, no 2, 1042-1048 p.Article in journal (Refereed) Published
Abstract [en]

Expression of human epidermal growth factor receptor type 3 (HER3) in malignant tumors has been associated with resistance to a variety of anticancer therapies. Several anti-HER3 monoclonal antibodies are currently under pre-clinical and clinical development aiming to overcome HER3-mediated resistance. Radionuclide molecular imaging of HER3 expression may improve treatment by allowing the selection of suitable patients for HER3-targeted therapy. Affibody molecules are a class of small (7 kDa) high-affinity targeting proteins with appreciable potential as molecular imaging probes. In a recent study, we selected affibody molecules with affinity to HER3 at a low picomolar range. The aim of the present study was to develop an anti-HER3 affibody molecule suitable for labeling with radiometals. The HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA HER3-specific affibody molecules were labeled with indium-111 (In-111) and assessed in vitro and in vivo for imaging properties using single photon emission computed tomography (SPECT). Labeling of HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA with In-111 provided stable conjugates. In vitro cell tests demonstrated specific binding of the two conjugates to HER3-expressing BT-474 breast carcinoma cells. In mice bearing BT-474 xenografts, the tumor uptake of the two conjugates was receptor-specific. Direct in vivo comparison of In-111-HEHEHE-Z08698-NOTA and In-111-HEHEHE-Z08699-NOTA demonstrated that the two conjugates provided equal radioactivity uptake in tumors, although the tumor-to-blood ratio was improved for In-111-HEHEHE-Z08698-NOTA [12 +/- 3 vs. 8 +/- 1,4 h post injection (p.i)] due to more efficient blood clearance. In-111-HEHEHE-Z08698-NOTA is a promising candidate for imaging of HER3-expression in malignant tumors using SPECT. Results of the present study indicate that this conjugate could be used for patient stratification for anti-HER3 therapy.

Place, publisher, year, edition, pages
2015. Vol. 34, no 2, 1042-1048 p.
Keyword [en]
NOTA, indium-111, affibody molecules, HER3, molecular imaging
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-260279DOI: 10.3892/or.2015.4046ISI: 000357965600060PubMedID: 26059265OAI: oai:DiVA.org:uu-260279DiVA: diva2:847784
Swedish Cancer SocietySwedish Research Council
Available from: 2015-08-21 Created: 2015-08-18 Last updated: 2015-08-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Rosestedt, MariaVarasteh, ZohrehTolmachev, VladimirOrlova, Anna
By organisation
Preclinical PET PlatformSection of Nuclear Medicine and PETMedical Radiation Science
In the same journal
Oncology Reports
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 413 hits
ReferencesLink to record
Permanent link

Direct link